Journal
MOLECULAR AND CELLULAR ENDOCRINOLOGY
Volume 489, Issue -, Pages 119-125Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.mce.2018.10.014
Keywords
HSD17B13; NAFLD; Lipid droplets; Genome-wide association study; Proteomics
Categories
Funding
- National Natural Science Foundation - Foundation of Shenzhen Basic Research Project [81500538/81500619/81870405]
- Natural Science Foundation of Shenzhen University [JCYJ20170818144501119]
- Robert A. Welch Foundation [2017093]
- [E - 0004]
Ask authors/readers for more resources
17 beta-Hydroxysteroid dehydrogenases (HSD17Bs) comprise a large family of 15 members that are mainly involved in sex hormone metabolism. Some HSD17Bs enzymes also play key roles in cholesterol and fatty acid metabolism. Recent study showed that hydroxysteroid 17 beta-dehydrogenase 13 (HSD17B13), an enzyme with unknown biological function, is a novel liver-specific lipid droplet (LD)-associated protein in mouse and humans. HSD17B13 expression is markedly upregulated in patients and mice with non-alcoholic fatty liver disease (NAFLD). Hepatic overexpression of HSD17B13 promotes lipid accumulation in the liver. In this review, we summarize recent progress regarding the role of HSD17B13 in the regulation of hepatic lipid homeostasis and discuss genetic, genomic and proteomic evidence supporting the pathogenic role of HSD17B13 in NAFLD. We also emphasize its potential as a biomarker of advanced liver disease, such as non-alcoholic steatohepatitis (NASH) and liver cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available